Figure 1.
![Figure 1. HLH disease features and viremias after treatment with emapalumab. (A-B) Absolute neutrophil and platelet counts, both heavily supported by transfusion until about day 21. (C-D) Fibrinogen (supported by fresh-frozen plasma transfusion until day 21) and D-dimer levels. (E-F) Alanine aminotransferase (ALT) and direct bilirubin levels. (G-H) The inflammatory markers ferritin and soluble interleukin-2 receptor (sIL2r [sCD25]). Reported ferritin values are limited to 40 000 μg/L by the clinical laboratory. Ferritin values decreased to <500 μg/L by day 180. (I-J) Blood levels of EBV and CMV. Arrows on the x-axis of each graph indicate the start of emapalumab treatment, and initial and final values for each marker are shown.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/3/1/10.1182_bloodadvances.2018025858/7/advances025858f1.png?Expires=1723181116&Signature=dLFkj5wjFagCarBEuWDN-e7laJID8XMRCjZ5--M81-VCzXWv0T9RwcUeGLZY51CMcjxkn6HpC9x7r8zX0a9HkX4W1hURyDctcvoOHQAaLuGtdfNtCPJv0bl6FuwCnrJmvzuMNJsm-UgWd3mSM-0BcJMHF35bMvzFbKKzoXO5qWTZGN9wVDWS2oDqcIcYByWaQVWiMulGeP3iEh7E34MDZFZF3vLflT3FNyFJZCUABgBc0jAE41JrnNfU-cN2q370MjGkRtYUkidHj86HQQJVxakJlF~XsVmJPIhQc8I4xOUJpyyen5R1S~An1-0oQTygIZGdAwQk53FTYl~54F8avg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
HLH disease features and viremias after treatment with emapalumab. (A-B) Absolute neutrophil and platelet counts, both heavily supported by transfusion until about day 21. (C-D) Fibrinogen (supported by fresh-frozen plasma transfusion until day 21) and D-dimer levels. (E-F) Alanine aminotransferase (ALT) and direct bilirubin levels. (G-H) The inflammatory markers ferritin and soluble interleukin-2 receptor (sIL2r [sCD25]). Reported ferritin values are limited to 40 000 μg/L by the clinical laboratory. Ferritin values decreased to <500 μg/L by day 180. (I-J) Blood levels of EBV and CMV. Arrows on the x-axis of each graph indicate the start of emapalumab treatment, and initial and final values for each marker are shown.